Shrinking pharmacological options in modern anaesthesia.

Abstract

Anaesthesia has become progressively safer through standardisation, technological advances, and pharmacological refinement. Paradoxically, the practical diversity of anaesthetic drugs available for routine clinical use is narrowing because of regulatory decisions, environmental policies, procurement pressures, market withdrawals, and professional convergence on default regimens. Although standardisation improves reliability, excessive pharmacological contraction can reduce clinical resilience, erode training competence with alternative agents, and increase vulnerability to shortages or context-specific contraindications. Stimulated by recent commentary that desflurane abandonment is only one component of a comprehensive sustainability strategy in anaesthesia, we argue that pharmacological diversity represents a form of preparedness: maintaining second-line and context-specific options is not inefficiency but a safeguard for patient-centred, adaptable care.